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Introduction
Quetiapine is an antipsychotic drug with a unique receptor-binding 
profile belonging to the same chemical class of the antipsychotic 
clozapine, the dibenzothiazepine derivatives and classified as an 
atypical or second generation antipsychotic [1,2]. This profile confers 
quetiapine a low risk of extrapiramidal effects and hiperprolactinemia 
[3].
Quetiapine is indicated for the treatment of schizophrenia and 
bipolar disorder. Schizophrenia is a common and serious mental 
disorder affecting around 0.7% of people at some point in their life. 
Its peak ages of onset are within the twenties; it is a chronic disabling 
disorder that affects young people and accounts for a disproportionate 
share of healthcare expenditures and loss of productivity [4]. Bipolar 
affective disorder, including the more classic form defined by the 
occurrence of manic or mixed episodes (bipolar I disorder) and the 
form defined by less severe hypomanic episodes (bipolar II disorder), 
is relatively common (combined lifetime incidence: approximately 3% 
to 5%), typically begins early in life (ie, before age 25), is associated 
with high rates of recurrence and chronicity, and results in significant 
morbidity. Due to these characteristics, bipolar affective disorder is one 
of the world’s greatest public health problems [5-7].
Quetiapine is metabolized by the liver. Less than 1% excreted as 
unchanged drug. Approximately 73% of dose recovered in urine and 
20% in feces. The mean terminal half-life for immediate-release is 
6 h, for ER is 7 h, and for N-desalkyl quetiapine is 12 h. Quetiapine 
appears to be the major circulating species in plasma. Unlike other 
antipsychotics such as olanzapine no effect of cigarette smoking on 
quetiapine clearance was observed. The pharmacokinetics of quetiapine 
are linear, and do not differ between men and women [8-10].
In order to avoid adverse reactions and unnecessary risks to the 
subjects, the study was conducted using the lowest dose (25 mg) of 
quetiapine, in compliance with the requirements of the Brazilian 
regulatory agency. It was taken into account that the pharmacokinetics 
of quetiapine is linear [8-10] and clinical trials must be carried out 
under conditions which ensure adequate safety of the subjects.
The objective of this study was to compare in healthy volunteers, 
the pharmacokinetics profiles and evaluate the bioequivalence of one 
test formulation of 25 mg tablet of quetiapine (kitapen®) manufactured 
by Cobalt Pharmaceuticals, Canada/ Arrow Farmacêutica Ltda* 
(Erowlabs). The test formulation was compared to 25 mg of quetiapine 
(Seroquel®) by Astrazeneca Brazil (reference formulation).
Methods
Study protocol
The study was performed in accordance with the Helsinki 
Declaration and Good Clinical Practice Guideline, and informed 
consent was obtained from participants prior to study commencement. 
The clinical part of the study was conducted at Scentryphar Clinical 
Research (Campinas City, São Paulo, Brazil) and the bioanalytical 
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Abstract
The study was performed to compare the bioavailability of two quetiapine 25 mg tablet formulations: the 
test formulation was quetiapine fumarate (kitapen®) manufactured by Cobalt Pharmaceuticals, Canada/ Arrow 
Farmacêutica Ltda* (Erowlabs). Seroquel® (quetiapine) from Astrazeneca Brazil was used as reference formulation. 
The study was conducted open with randomized two period crossover design and one week wash out period in 
64 volunteers of both sexes. Plasma samples were obtained over a 48 hour interval. Quetiapine was analyzed by 
LC-MS-MS in the presence of quetiapine-D8 as internal standard. Plasma samples were obtained over a 48 hour 
interval. Quetiapine was analyzed by LC-MS-MS in the presence of quetiapine-D8 as internal standard. The mean 
ratio of parameters Cmax and AUC0-t and 90% confidence intervals of correspondents were calculated to determine 
the bioequivalence. The means AUC0-t for test and reference formulation were 432.41 ng.h/mL and 412.20 ng.h/mL, 
for AUC0-∞ were 440.06 ng.h/mL and 418.90 ng.h/mL and, for Cmax 126.94 ng/mL and 108.71 ng/mL, respectively. 
Geometric mean of quetiapine (kitapen®)/Seroquel® 25 mg individual percent ratio was 97.68% AUC0-t, 97.47% 
for AUC0-∞ and 90.68% for Cmax. The 90% confidence intervals were  92.67 – 102.96%, 92.53 – 102.67%, 83.37 – 
98.64%, respectively. Since the 90% confidence intervals for Cmax, AUC0-t and AUC0-∞ were within the 80 – 125% 
interval proposed by Food and Drug Administration, it was concluded that quetiapine (kitapen®) 25 mg tablet was 
bioequivalent to Seroquel® 25 mg tablet according to both the rate and extent of absorption.
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part at Nucleus of Bioequivalence and Clinical Research/NUBEC (São 
Paulo, Brazil).
Subjects
Sixty four healthy volunteers of both sexes (32 males and 32 
females) who were between the ages of 18 and 48 (mean ± SEM: 30.84 ± 
8.03 years), who had heights between 144.00 cm and 182.00 cm (165.00 
± 0.08 cm), and who weighed between 49.10 kg and 88.00 kg (66.19 ± 
9.45 kg) and within 15% of their ideal body weight were enrolled in 
the study. Subjects were judged eligible for enrolment in this study if 
they were in compliance with all the inclusion and exclusion criteria 
described in the protocol.
All the subjects provided written informed consent to participate 
after explaining the nature and purpose of the study. The study protocol 
was approved by the University of Campinas/Unicamp with the ethical 
principles described in the Declaration of Helsinki, guidelines for 
International Conference on Harmonization-Good clinical practices 
(ICH-GCP).
All volunteers were healthy as assessed by physical examination, 
ECG, and the following laboratory tests: blood glucose, urea, creatinine, 
AST, ALT, alkaline phosphatase, Gamma GT, total bilirrubin, albumin 
and total protein, triglycerides, total cholesterol, hemoglobin, 
hematocrit, total and differential white cell counts and routine urine. 
All subjects were negative for HIV, HBV (except for serological scare) 
and HCV.
Drug products 
The test formulation employed was quetiapine (kitapen®) 25 mg 
tablet (lot number ZA77) and the reference formulation was: Seroquel® 
25 mg tablet (lot number 80915).
Study design
The study was performed to compare the bioavailability of two 
quetiapine 25 mg tablet formulations under fasting conditions: the test 
formulation was fumarato de quetiapina (kitapen®). Seroquel® from 
Astrazeneca Brazil was used as reference formulation. The formulation 
was tested for bioequivalence for the first time.
The study was conducted in an open randomized 2 period 
crossover balanced design with a 1 week wash out period between the 
doses. During each period, the volunteers were hospitalized at 8:00 
pm having already had a normal evening meal, and after an overnight 
fast they received at 7:00 am a single 25 mg tablet quetiapine dose of 
either formulation. Water (200 mL) was given immediately after drug 
administration. All volunteers were then fasted 05 hours following the 
drug administration, after which a standard lunch was consumed and 
an evening meal was provided 10 hours after dosing. No other food 
was permitted during the “in-house” period. Liquid consumption 
was permitted ad libitum after lunch but xanthine-containing drinks 
including tea, coffee and cola were avoided. Systolic and Diastolic 
arterial pressure (measured on invasively with a sphygmomanometer 
automatic by Omron equipment), heart rate and temperature were 
recorded just before and hourly after drug administration.
Blood samples (06 mL) from a suitable antecubital vein were 
collected into EDTA containing tubes before and 0.10, 0.20, 0.30, 0.40, 
0.50, 1.00, 1.10, 1.20, 1.40, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 
24.00, 48.00 hours after administration of each quetiapine 25 mg tablet.
Drug analysis
Blood samples were cooled in a bath and centrifuged at 3.000 
rpm for at least 10 min at approximately 4°C. At least 3mL of plasma 
were dispensed into polypropylene tubes. Sample tubes were frozen at 
–20°C, and maintained to that temperature until analysis. All samples 
from a single volunteer were analyzed on the same day in order to avoid 
inter assay variation.
Plasma concentrations of quetiapine were determined by the HPLC 
coupled with tandem mass spectrometry (LC/MS/MS), in positive ion 
electrospray ionization mode, using a multiple monitoring (MRM) 
method and isotopic labeled quetiapine-D8 as internal standard 
(IS). The transitions used were 384.6 → 253.0 for quetiapine and 
392.6 → 253.0 for IS. This apparatus consisted of a Shimadzu LC-
10ADvp pump, an on line SPE system - Prospekt-2™ Spark Holland 
and Micromass QuattroLC triple-quadrupole mass spectrometer. The 
analytes were extracted automatically from plasma using on line solid 
phase extraction, with Hysphere HD C18 cartridges. The method 
was validated for selectivity, linearity, precision, accuracy, extraction 
recovery and stability.
The analytical column was a Chromolith–RP18, 100 x 4.6 mm, 5μ 
(Merck). The mobile phase used, in isocratic mode, was a mixture of 
acetonitrile, methanol and water (30:20:50 v/v), containing 20 mM 
acetic acid. 
Pharmacokinetic analysis and statistical analysis
The first-order terminal elimination rate constant (Ke) was estimated 
by linear regression from the points describing the elimination phase 
on a log-linear plot, using the software SAS® Institute (Version 9.1.3). 
Elimination half-life (T1/2) was derived from this rate constant (T1/2 
= ln (2)/Ke). The maximum observed plasma concentration (Cmax) 
and the time taken to achieve this concentration (Tmax) were obtained 
directly from the curves. The areas under the quetiapine metabolite 
plasma concentration versus time curves from 0 to 48 hours (AUC0-48h) 
were calculated by applying the linear trapezoidal rule. Extrapolation of 
these areas to infinity (AUC0-∞) was done by adding the value C48/Ke 
to the calculated AUC0-48h (where C48=plasma concentration calculated 
from the log-linear regression equation obtained for the estimation of 
Ke 48 hours after dose).
The bioequivalence between both formulations was assessed by 
calculating individual Cmax, AUC0-48h, AUC0-∞ and Cmax/AUC0-48h ratios 
(test/reference) together with their mean and 90% confidence intervals 
(CI) after log transformation of the data. The inclusion of the 90% CI 
for the ratio in the 80% to 125% range was analyzed by nonparametric 
(SAS® Institute Version 9.1.3) and parametric (ANOVA) methods.
Results
Tolerability analysis
Quetiapine was well tolerated at the administered dose. All the 
biochemical parameters did not any clinical relevant alterations. No 
adverse effects serious were either reported or observed.
Method validation
The calibration curves were linear in the ranges of 0.2 – 200 ng/mL 
(R2 ≥ 0,99) by using least square linear regression analysis with a weight 
factor of 1/x. The precision and accuracy were obtained by the analysis 
of tree batches of QC samples (LLOQ, low, medium and High QCs) 
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and the intra and inter day RSDs were no more than 8.3%, indicating 
acceptable precision and accuracy of the present method.
The extraction recoveries of quetiapine and IS from human plasma 
were 75.70 ± 3.92 % and 79.74 ± 4.00 %, respectively.
The stability of stock solutions of quetiapine and IS were accessed 
and found stable at room temperature for 6 h and at 4ºC for 60 days. 
The analytes in plasma stored at room temperature for 6 h, at 4ºC for 7 
days, at -20ºC for 100 days and during the three freeze and thaw cycles 
indicated the good stability of quetiapine and IS during the study.
Pharmacokinetic and statistical analysis
The mean (± SD) plasma concentration time profile of the 2 
formulations, shown in Figure 1, was similar and super imposable. 
Central and dispersion measures for all pharmacokinetic 
parameters for both formulations are shown in Table 1 and Table 2. 
From this, the mean values of Cmax were found to be 126.94 (± 67.80 
standard deviations [SD]) ng/mL for the reference product and 108.71 
(± 41.63) ng/mL for the locally manufactured (test) product. For Tmax 
(h), the mean values were found to be similar for both the reference and 
local product and the value was 5.52 (5.38) h. The mean values of AUC0-
48 were found to be 432.41 (± 259.23) ng.h/mL for reference and 412.20 
(± 217.26) ng.h/mL for local product. The mean AUC0-∞ were found to 
be 440.06 (± 260.24) ng.h/mL and 418.90 (± 218.22) ng.h/mL for the 
reference and locally manufactured product, respectively.
Table 3 presents the ratios and the respective confidence intervals 
for bioequivalence analysis.
Discussion
Due to increasing increasing use of quetiapine in the clinical 
practice, which encourages the development of new pharmaceutical 
preparations, there is an increasing demand for new analytical methods 
for determination of quetiapine. Several HPLC methods for the 
determination of quetiapine have been reported. None of these methods 
is sensitive enough for determination of the expected drug levels 
and some of them are timeconsuming and require complex sample 
pretreatment or long run times. The quantification of various drugs 
by chromatography with tandem mass spectrometry is if becoming 
each more common time due to improvement in the sensitivity 
and the selectivity of this method [11-19]. With the advance of the 
chromatography the quality in the determination of the concentrations 
is more precise, getting a lower LOQ and better analysis of results. The 
analytical method presented here for the determination of quetiapine 
was analyzed by LC-MS-MS. No interferences from endogenous 
Figure 1: Mean plasma concentration-time profile of quetiapine over the first 
48 h after oral administration of the test and reference formulation.
TEST REFERENCE
Parameter (unit) Means(Median)
Standard
Deviation
(Amplitude)
Means
(Median)
Standard
Deviation
(Amplitude)
AUC0-t (ng.h/mL) 412.20 217.26 432.41 259.23
AUC0-inf (ng.h/mL) 418.90 218.22 440.06 260.24
Cmax (ng/mL) 108.71 41.63 126.94 67.80
Tmax (median/amp) (h) 1.00 3.50 1.00 2.50
Kel (1/h) 0.14 0.05 0.14 0.05
T½ (median/amp) (h) 5.38 7.19 5.52 17.07
Table 1: Mean pharmacokinetic parameters of quetiapine of test and reference formulation.
TEST REFERENCE
Parameter (unit) Geometric Mean Geometric Mean
AUC0-t (ng.h/mL) 369.21 377.99
AUC0-inf (ng.h/mL) 376.15 385.92
Cmax (ng/mL) 101.06 11.45
Table 2: Geometric mean pharmacokinetic parameters of quetiapine of test and reference formulation.
Parameter Ratio T/R(%)
Lower Limit
(%)
Upper Limit
(%)
Power
(%)
Coefficient of Variation
(%)
AUC0-t 97.68 92.67 102.96 99.99 17.53
AUC0-inf 97.47 92.53 102.67 99.99 17.30
Cmax 90.68 83.37 98.64 79.29 28.34
Tmax (dif) (h) 0.00 0.00 0.17 - -
Table 3: Rations means and the 90% geometric confidence interval of test and reference formulation.
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plasma components or other sources were found and no “cross-talk” 
was observed in plasma samples. The assay showed good precision 
and accuracy. The analytical method has been proved useful for the 
investigation of the characteristics of quetiapine in human plasma in 
pharmacokinetic studies. 
The bioavailability of a pharmaceutical form refers to the extent 
and speed of absorption of the active principle in contained it. Two 
pharmaceutical forms are said bioequivalent when administered to the 
same individual, in the same experimental conditions and at the same 
dose, they show no significant differences in relation to bioavailability. 
In this study two formulations of quetiapine had been evaluated. 
Washout period was adequate, there was no quantifiable concentration 
of the drugs in the second period of the study, indicating that there 
was no carryover effect from the first to the second period. The mean 
ratio of parameters Cmax and AUC0-t and 90% confidence intervals of 
correspondents were calculated to determine the bioequivalence. The 
means AUC0-t for test and reference formulation were 432.41 ng.h/mL 
and 412.20 ng.h/mL, for AUC0-∞ were 440.06 ng.h/mL and 418.90 ng.h/
mL and, for Cmax 126.94 ng/mL and 108.71 ng/mL, respectively. The 
ratios were 97.68% for AUC0-t, 97.47% for AUC0-∞ and 90.68% for Cmax. 
The 90% confidence intervals were 92.67 – 102.96% for AUC0-t, 92.53 – 
102.67% for AUC0-∞ and 83.37 – 98.64% for Cmax.
The AUC0-t and AUC0-∞ are both recognized as an uncontaminated 
measurement of the extent of absorption. The present study showed 
that 90% CI of mean AUC0-t and AUC0-∞ (after log-transformation of 
individual ratios) were included into the bioequivalence range (80-
125%), consequently, the two formulations of quetiapine are equivalent 
for the extend of absorption.
The statistical comparison of Cmax, AUC0-t and AUC0-∞ clearly 
indicated no significant difference in the two formulations of quetiapine 
25 mg tablet. 90% confidence intervals for the mean ratio (T/R) of 
Cmax, AUC0-t and AUC0-∞ were entirely within the US Food and Drug 
Administration acceptance range. Based on the pharmacokinetic and 
statistical results of this study, we can conclude that quetiapine 25 mg 
tablet (kitapen®, manufactured by Cobalt Pharmaceuticals, Canada/ 
Arrow Farmacêutica Ltda* (Erowlabs) is bioequivalent to Seroquel® 25 
mg tablet (Astrazeneca, Brazil), and that then the test product can be 
considered interchangeable in medical practice.
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